Clinical Trial Update: A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain [Phase 1]

View source ↗

Summary

A Phase 1, repeated-dose study evaluating the metabolism and pharmacologic action of OROS Hydromorphone HCl slow-release tablets in chronic pain patients has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• OROS Hydromorphone HCl Slow Release Tablets (hydromorphone hydrochloride)

Snippet

Sponsor: Alza Corporation, DE, USA | Conditions: Pain, Analgesics, Opioid | Phase 1 | Status: COMPLETED